Readoutin 165d
Sun Pharmaceutical Industries, Inc. — CTP-543
Phase 3 primary completion: Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata.
- Date
- May 2027
- Type
- Readout
- Indication
- Alopecia Areata
Readoutin 165d
Phase 3 primary completion: Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata.
The weekly brief is free. Pro adds reminders 7 days and 1 day before.